Aripiprazole Tablet
Product Images NDC 50090-4936

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 50090-4936). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Aripiprazole-fig-16.jpg (Aripiprazole Fig 16)

A Kaplan-Meier plot showing the proportion of subjects with relapse over days from randomization, comparing Aripiprazole and placebo groups. The x-axis represents the duration in days, while the y-axis reflects the relapse proportion. The graph includes the number of subjects at risk at various time points for both groups.*

FDA Label Image

Aripiprazole-fig-17 (Aripiprazole Fig 17)

A line graph showing the proportion with relapse over days from randomization comparing Aripiprazole (solid blue line) and Placebo (dashed red line). The x-axis represents days from randomization (0 to 364), and the y-axis shows the proportion with relapse (0 to 1.0). Below the x-axis is the number of subjects at risk for each group at various time points.*

FDA Label Image

Effects Of Other Drugs On Dehydro-aripiprazole (Aripiprazole Fig10)

A pharmacokinetic chart showing the fold change and 90% confidence intervals of dehydro-aripiprazole levels relative to reference without interacting drugs. The graph compares the effects of various inhibitors, inducers, and other drugs (ketoconazole, quinidine, carbamazepine, famotidine, valproate, lithium, lorazepam) on AUC and Cmax parameters, illustrating drug interaction impacts on aripiprazole metabolism.*

FDA Label Image

Effects Of Aripiprazole On Pharmacokinetics Of Other Drugs (Aripiprazole Fig11)

A bar chart depicting fold changes with 90% confidence intervals for pharmacokinetic parameters (AUC and Cmax) and INR related to various drugs, including dextromethorphan, warfarin (S-warfarin and R-warfarin), omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine (including O-desmethylvenlafaxine), and escitalopram. The x-axis shows the change relative to a reference without interacting drugs, ranging from 0.5 to 3.0.*

FDA Label Image

Effects Of Intrinsic Factors On Aripiprazole (Aripiprazole Fig12)

A pharmacokinetic chart illustrating Aripiprazole fold change and 90% confidence intervals for different factors such as CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, and severe renal impairment. The x-axis shows change relative to reference from 0.5 to 3.0, and the y-axis lists various categories with AUC and Cmax parameters.*

FDA Label Image

Effects Of Intrinsic Factors On Dehydro-aripiprazole (Aripiprazole Fig13)

A forest plot chart titled 'Dehydro-Aripiprazole Fold Change and 90% CI' showing pharmacokinetic comparisons of AUC and Cmax changes relative to reference across groups including CYP2D6 metabolizer status, gender, age, hepatic impairment levels, and severe renal impairment. The X-axis represents change relative to reference from 0.5 to 3.0.*

FDA Label Image

Effects Of Other Drugs On Aripiprazole (Aripiprazole Fig9)

A pharmacokinetic chart titled 'Aripiprazole Fold Change and 90% CI' showing the relative change in AUC and Cmax for aripiprazole with various interacting drugs. The x-axis represents change relative to reference (without interacting drug), and the y-axis lists CYP3A4 inhibitors, CYP2D6 inhibitors, CYP3A4 inducers, gastric acid blockers, and other drugs. The data points show fold changes with 90% confidence intervals for each drug interaction.*

FDA Label Image

Aripiprazole Structure (Aripiprazole Fig8)

Chemical structure diagram of Aripiprazole, the active ingredient in the product. The structure shows the arrangement of rings and functional groups characteristic of Aripiprazole.*

FDA Label Image

Aripiprazole-graph (Aripiprazole Graph)

A Kaplan-Meier curve chart showing the proportion of subjects with relapse over time (days from randomization) comparing Aripiprazole to placebo. The graph includes a key with solid blue line for Aripiprazole and dashed red line for placebo and presents the number of subjects at risk for both groups at various time points below the x-axis.*

FDA Label Image

Label Image (Lbl500904936)

Aripiprazole 10 mg oral tablet packaging label from A-S Medication Solutions. The label includes the NDC 50090-4936-1 and indicates each tablet contains 10 mg of Aripiprazole. Storage instructions specify to store at 77 degrees Fahrenheit. The package size is 30 tablets. Additional identifiers such as product number and GTIN are also visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.